Clinical Trial

A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The main objective of this trial will be to determine whether maridebart cafraglutide is superior to placebo on reduction in liver fat content and body weight in participants living with obesity or overweight and elevated liver fat content, when administered in conjunction with reduced-calorie diet and increased physical activity.
Protocol Amendment History 3 changes
notable Trial sites expanded: 18 -> 21 locations 2026-05-23
notable Trial sites expanded: 15 -> 18 locations 2026-05-06
notable Trial sites expanded: 10 -> 13 locations 2026-04-10
Trial Details
NCT Number NCT07441252
Lead Sponsor Amgen
Conditions Overweight or Obesity and Elevated Liver Fat
Enrollment 180 participants
Start Date 2026-03-05
Primary Completion 2027-09-29 (estimated)
Study Completion 2027-12-22 (estimated)
Updated on ClinicalTrials.gov 2026-06-18